Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leads Out in Psychedelic-Based Therapeutics Space
07. März 2022 08:30 ET
|
Cybin Inc.
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for...
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics
03. März 2022 08:30 ET
|
Cybin Inc.
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...
Cybin Inc. (NEO: CYBN) at Forefront of Psychedelic Revolution
26. März 2021 08:30 ET
|
Cybin Inc.
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Science Drives Surging Interest in Psychedelic...
Cybin Inc. (NEO: CYBN) in Prime Position as Interest in Psychedelic Medicine Surges
25. März 2021 08:30 ET
|
Cybin Inc.
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands...
Cybin Inc. (NEO: CYBN) Looking to Solve Long-Standing Problem with MDD Treatment
18. Dezember 2020 08:30 ET
|
Cybin Inc.
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “Hope on the Horizon: Psychedelics Offer Potential for...
Cybin Inc. (NEO: CYBN) Acquisition, Three-Pillar Approach Reason for Optimistic MDD Outlook
17. Dezember 2020 08:30 ET
|
Cybin Inc.
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
14. Dezember 2020 08:51 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
14. Dezember 2020 08:07 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
New Study Finds Psychedelic Treatments More Effective than Typical Antidepressant Medications
13. November 2020 08:30 ET
|
Cybin Inc.
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Cybin Inc. (NEO: CYBN) announces the availability of a broadcast titled, “On the Trail of Better Therapeutics for Depression.” To...
New Therapeutic Protocols Targeting Debilitating Disorders on the Horizon
11. November 2020 08:30 ET
|
Cybin Inc.
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands...